

Associations of proton pump inhibitors with susceptibility to pneumonia, influenza, and COVID-19: evidence from a large population based cohort study

Ruijie Zeng, MD^{1,2,3}; Yuying Ma, MD^{1,2}; Lijun Zhang, MD^{1,4}; Dongling Luo, MD⁵; Rui Jiang, BS^{1,4}; Huihuan Wu, MD^{1,4}; Zewei Zhuo, MS¹; Qi Yang, BS¹; Jingwei Li, MD^{1,4}; Felix W Leung, MD, PhD^{*6,7}; Qian Chen, PhD^{*8,9,10}; Weihong Sha, MD, PhD^{*1,2,3,4}, Hao Chen, MD, PhD^{*1,2,3,4}

¹Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

²The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China

³Shantou University Medical College, Shantou 515000, Guangdong, China

⁴School of Medicine, South China University of Technology, Guangzhou 510006, China

⁵Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China

⁶David Geffen School of Medicine, University of California Los Angeles, Los Angeles 90032, California, USA

⁷Sepulveda Ambulatory Care Center, Veterans Affairs Greater Los Angeles Healthcare System, North Hills 16111, California, USA

⁸Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

⁹Guangdong Provincial Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou 510120, China

¹⁰School of Public Health, Sun Yat-sen University, Guangzhou 510080, China

****Correspondence:***

Prof. Felix W Leung, David Geffen School of Medicine, University of California Los Angeles, Los Angeles 90032, California, USA; E-mail: Felix.Leung@va.gov

Dr. Qian Chen, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China; Email: chenq353@mail.sysu.edu.cn

Prof. Weihong Sha, Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; E-mail: shawei hong@gdph.org.cn

Prof. Hao Chen, Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China; E-mail: chenhao@gdph.org.cn

[†]: These authors contributed equally to this work

Abstract

Objective Concerns have been raised about the widespread use of proton pump inhibitors (PPIs), and current findings linking the regular use of PPIs to respiratory infections remain inconsistent. Our study aims to evaluate whether PPI use increases the risk of pneumonia, influenza, and COVID-19.

Method The presented study included 160,923 eligible participants from the UK Biobank (mean age 56.5 years, 53% women). Cox proportional hazards regression and propensity score-matching analyses were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). Effect modifications by stratifications, including indications and *CYP2C19* phenotypes were tested.

Results The regular use of PPIs was associated with increased risks of developing pneumonia (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.26-1.59) and influenza (HR 1.31, 95% CI 1.11-1.55). However, the risk of COVID-19 infection among regular PPI users was not significantly increased (HR 1.05, 95% CI 0.95-1.16). The burden was more notably observed in patients without indications of PPI use (HR 1.52, 95% CI 1.33-1.73 for pneumonia; HR 1.36, 95% CI 1.12-1.64 for influenza). The risk for pneumonia was higher among the *CYP2C19* rapid and ultrarapid metabolizers (HR 1.45, 95% CI 1.22-1.73, *P* for interaction < 0.001). The propensity score-matching analyses yielded similar trends.

Conclusions The regular use of PPIs is associated with increased susceptibility to pneumonia and influenza, but not COVID-19 infection. The risks are even higher among recipients without main indications. Our study highlights the appropriate use and de-prescribing of PPIs according to indications and *CYP2C19* phenotypes for patients and clinical practitioners.

Keywords

Proton pump inhibitor, Pneumonia, Influenza, COVID-19, UK Biobank

What is already known on this topic

- Proton pump inhibitors (PPIs) have been extensively used in clinical practice, while emerging studies suggest the adverse effects associated with their long-term use.
- The linkage between PPIs and respiratory infections has been indicated, whereas controversy remains.

What this study adds

- In the large cohort involving 160,923 individuals, regular use of PPIs was associated with 42% and 31% increased risks of pneumonia and influenza, respectively, but not COVID-19 infection.
- The burdens were more evident among PPI users without main indications, and *CYP2C19* rapid and ultrarapid metabolizers.

How this study might affect research, practice or policy

- Considering the potential risk of respiratory infections, appropriate use following indications and metabolic phenotypes, as well as de-prescribing of PPIs are highlighted.

1. Introduction

Proton pump inhibitors (PPIs), as one of the most commonly used medications worldwide, have been utilized for treating various conditions related to excessive gastric acid secretion [1]. In the United States, the prescription of PPIs has doubled from 1999 to 2012, and the number of people taking PPIs is still increasing due to their availability over the counter [2]. However, concerns are being raised regarding the long-term and inappropriate use of PPIs, which have been linked to a wide range of adverse conditions, including osteoporotic fractures, renal failure, and vitamin deficiencies [3-5].

Since PPI-induced hypochlorhydria could advantage the gastrointestinal residence of pathogens, apprehensions have also been aroused for respiratory infections over the past two decades [6]. Cohort studies in the United Kingdom and the United States reveal the risks of developing community- and hospital-acquired pneumonia are increased by approximately 100% and 30%, respectively [7, 8]. In contrast, a nested case-control study based on the UK General Practice Research Database indicates long-term PPI therapy is not associated with increased risk for community-acquired pneumonia [9], and a retrospective cohort study involving 593 265 patients in Canada demonstrates no increased risk in developing pneumonia among PPI recipients [10]. Recently, attention has also been paid to the susceptibility to Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on 53,130 participants in the United States, a dose-dependent increased risk of COVID-19 positivity among PPI users is found [11]. Another Danish study also indicate a marginally increased risk of COVID-19 positivity [12], whereas studies based on the UK Biobank and a Korean cohort indicate nonsignificant association [13, 14].

Controversy remains among the current evidence, while previous studies might suffer from insufficiency in study design and outdated data. For instance, the study based on the UK General Practice Research Database did not adjust for potential confounding variables for PPI indications [15]. In addition, the findings by Almario *et al.* were based on patients with gastrointestinal symptoms, rather than the general population [11]. The previous UK Biobank study merely included participants tested for COVID-19 from March to June 2020 [13].

In view of the widespread and frequent use of PPIs, it is necessary to carefully examine their related adverse outcomes. Herein, by leveraging the large-scale cohort data in the UK Biobank, we aim to evaluate the associations between the regular use of PPIs and the susceptibility to respiratory infections, mainly including pneumonia, influenza, and COVID-19.

2. Methods

2.1 Study population

The detailed information on study design for the UK Biobank was demonstrated previously [16]. In brief, over 0.5 million participants aged 37 to 73 years were recruited from 22 assessment centers in the United Kingdom from 2006 to 2010, and they had to be capable of attending the assessment centers. Written informed consent was acquired from each participant, and ethical approval was obtained from the North West Multi-Center Research Ethics Committee (approval number: 11/NW/0382, 16/NW/0274, and 21/NW/0157). The current study has been approved under the UK Biobank project 83339.

In this study, 11,171 participants with missing PPI medication data, 273,412 individuals without primary care data, and 56,907 participants with missing covariate data were excluded. Among them, 1,298 participants without follow-up had been all removed after initial exclusion. For the evaluation of associations with pneumonia, influenza, and other respiratory infections, those only with self-reported records and diagnoses were further excluded. For the COVID-19-related outcomes, we excluded participants without COVID-19 testing data or who had died before the COVID-19 pandemic (**Figure 1**).

2.2 Definition of exposure

The exposure of interest was regular use of PPIs. Verbal interviews were conducted by a trained nurse if participants answered that they were taking regular prescription of medication on the touchscreen, in which 'regular' was defined as most days of the week for the last 4 weeks, and information on specific types of medications were further recorded. Short-term medications, for example, 1-week course of antibiotics, were not recorded in the interview. Types of PPIs available in the UK Biobank included omeprazole, lansoprazole, esomeprazole,

rabeprazole, and pantoprazole. Information on dose or duration of PPI use was not available in the UK Biobank.

2.3 Definition of outcomes

The primary outcomes of interest were pneumonia, influenza, COVID-19 infections (**Supplementary Table 1**). Briefly, the first reported occurrences of respiratory system-related conditions within the International Classification of Diseases (ICD-10) were categorized by the UK Biobank. Pneumonia was defined as that caused by viruses, bacteria, and other infectious organisms (J12-18). Influenza included the ones caused by identified influenza viruses or unidentified viruses (J09-12). The definition of other upper respiratory infections contained acute nasopharyngitis, sinusitis, pharyngitis, tonsillitis, laryngitis, tracheitis, obstructive laryngitis, epiglottitis, or upper respiratory infections of multiple and unspecified sites (J00-J06). Other lower respiratory infections included acute bronchitis, bronchiolitis, and other unspecified ones (J20-J22).

Updated COVID-19-related data available from March 2020 to January 2022 in the UK Biobank was used. COVID-19 infection mainly included information on positive COVID-19 tests, and patients with the inpatient diagnosis or mortality due to COVID-19 were also regarded as having COVID-19 infection. The secondary outcomes included COVID-19 mortality and severity. Severe COVID-19 cases were defined as being hospitalized for COVID-19. COVID-19 mortality was defined as the underlying recorded cause of death due to COVID-19 (ICD-10 U07.1 and U07.2).

2.4 Assessment of covariates

Baseline data on sociodemographic information (age, sex, ethnicity), socioeconomic status (deprivation index), lifestyle factors (alcohol consumption, smoking status), fresh fruit intake, and body mass index (BMI) were collected from the UK Biobank. Physical activity was assessed using the International Physical Activity Questionnaire-Short Form. Indications of PPIs, mainly containing gastroesophageal reflux disease (GERD), peptic ulcers, and upper gastrointestinal bleeding, were included. The comorbidities (hypertension, type 2 diabetes, renal failure, myocardial infarction, stroke, chronic obstructive pulmonary disease [COPD],

asthma) were examined using self-reported data. Data on medication use including histamine 2 receptor Antagonist (H2RA), aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NSAIDS, including ibuprofen), cholesterol-lowering medications, as well as multivitamin use were extracted.

2.5 CYP2C19 genetic variants

Genotyped genetic variant data after quality control was available for UK Biobank participants based on the Affymetrix Axiom UKB array and the Affymetrix UKBiLEVE array [17]. According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2C19* and Proton Pump Inhibitor Dosing [18], genotypic data of four *CYP2C19* variants, including *rs12248560* (*CYP2C19*17*), *rs17884712* (*CYP2C19*9*), *rs4986893* (*CYP2C19*3*), and *rs4244285* (*CYP2C19*2*), were utilized to divide PPI users into three subgroups: (1) *CYP2C19* rapid and ultrarapid metabolizers; (2) *CYP2C19* normal metabolizers; (3) *CYP2C19* likely intermediate, intermediate and poor metabolizers.

2.6 Statistical analysis

The baseline characteristics were demonstrated by percentages for categorical variables, and mean (standard deviation [SD]), or median (interquartile range [IQR]) for continuous variables according to the distribution of data.

Univariate and multivariate Cox proportional hazards regression models were utilized to assess the association between regular use of PPIs and the selected outcomes, and the results were presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Multivariable model 1 included age and sex. Model 2 additionally contained other potential confounders selected *a priori*, including ethnicity, deprivation index, alcohol consumption, smoking, physical activity, BMI, fresh fruit intake, GERD, peptic ulcer, upper gastrointestinal bleeding, hypertension, type 2 diabetes, renal failure, myocardial infarction, stroke, COPD, asthma, aspirin, non-aspirin NSAIDS, H2RA, cholesterol-lowering medications, and multivitamin use. The reference group was participants without regular use of PPIs. Schoenfeld residuals tests were used to evaluate the proportional hazards assumptions, while no violation of the assumption was detected. Person-years were calculated from the

recruitment date to the date of outcome diagnoses, last follow-up (January 2022 for COVID-19-related outcomes; December 2021 for other outcomes), or death, whichever came first. Stratified analyses according to population characteristics, types of PPIs, and *CYP2C19* metabolizers were performed using multivariable models, and the multiplicative interaction were tested.

In addition, propensity score-matching analysis was conducted. The same set of covariates was used to derive propensity scores, and the PPI users and non-users were matched with a ratio of 1:4 using the nearest neighbor caliper matching method without replacement. The remaining imbalanced covariates (standardized mean difference ≥ 0.1) after propensity score matching were further adjusted by multivariate Cox regression models to calculate HRs and 95% CIs [19].

All statistical analyses were performed using R (version 4.2.0, <https://www.r-project.org/>). The significance level at $\alpha = 0.05$ with two tails was used.

3. Results

3.1 Study population

A total of 160,923 individuals aged 38 to 71 years who passed the initial selection criteria in the UK Biobank were included in this study (**Table 1**). The median follow-up was 7.1 (interquartile range [IQR] 6.2-8.5) years. The mean age of the included participants was 56.5 years, and 53.0% of them were women. Evidently, regular PPI users were characterized by higher rates of GERD (32.4% vs. 2.7%), peptic ulcer (5.6% vs. 0.9%), and upper gastrointestinal bleeding (0.2% vs. 0.03%) compared to non-regular PPI users. Higher burdens of comorbidities, as well as increased use of aspirin, H2RA, and cholesterol-lowering medications, were also observed in regular PPI users.

3.2 Proton pump inhibitor use and pneumonia, influenza, and other respiratory infections

Increased risks of developing pneumonia, influenza, and other respiratory infections were identified in regular users of PPIs compared with non-regular users, and the results remained

significant after adjustments (**Table 2**). Regular use of PPIs was associated with a 42% increased risk of developing pneumonia (fully adjusted HR [aHR] 1.42, 95% CI 1.26-1.59, $P < 0.001$). In addition, a 31% increased risk of developing influenza (aHR 1.31, 95% CI 1.11-1.55, $P = 0.001$) was observed among regular PPI users. For other upper and lower respiratory infections, the risks among regular PPI users were increased by 19% (aHR 1.19, 95% CI 1.11-1.27, $P < 0.001$) and 37% (aHR 1.37, 95% CI 1.29-1.46, $P < 0.001$), respectively.

3.3 Proton pump inhibitor use and COVID-19-related outcomes

The associations of PPI use with COVID-19 positivity, severity, and mortality were further evaluated in our study. Initially, in the non-adjusted and age/sex-adjusted models, the susceptibility to COVID-19 positivity was observed with a 1.34- and 1.26-fold increase (HR 1.34, 95% CI 1.23-1.47, $P < 0.001$ for non-adjusted model; HR 1.26, 95% CI 1.16-1.38, $P < 0.001$ for age/sex-adjusted model; **Table 2**) in participants with regular use of PPIs. However, full adjustments for covariates rendered the association nonsignificant (aHR 1.05, 95% CI 0.95-1.16, $P = 0.335$; **Table 2**). Risks of developing severe COVID-19 (aHR 1.27, 95% CI 0.99-1.62, $P = 0.055$) and fatality due to COVID-19 (aHR 1.02, 95% CI 0.90-1.12, $P = 0.785$) were also attenuated and became nonsignificant after fully adjusting for covariates (**Supplementary Table 2**).

3.4 Subgroup analysis

Stratified analyses were performed in the fully adjusted models for the three main outcomes, including influenza, pneumonia, and COVID-19 positivity. Overall, it is noticeable that participants without any indication of PPIs suffered from significantly higher susceptibility to pneumonia compared with regular users with main indications (aHR 1.52, 95% CI 1.33-1.73 vs. aHR 1.12, 95% CI 0.87-1.44, $P = 0.04$, **Figure 2**). Although the comparison was not statistically significant for influenza or COVID-19 positivity, similar trends were demonstrated (aHR 1.36, 95% CI 1.12-1.64 vs. aHR 1.16, 95% CI 0.82-1.64 for influenza; aHR 1.10, 95% CI 0.98-1.22 vs. aHR 0.87, 95% CI 0.71-1.08 for COVID-19 positivity; **Figure 2**).

Regarding the risk of developing pneumonia, regular PPI users who were older than 60 years, took aspirin, or had cholesterol-lowering medications were at significantly greater risk.

The PPI-associated risk of influenza did not significantly differ within different subgroups. The risks of COVID-19 positivity remained nonsignificant in the stratifications (**Figure 2**).

Among different types of PPIs, regular omeprazole users were correlated with greater risks for pneumonia, influenza, and other upper and lower respiratory infections (**Supplementary Table S3**). Regular use of lansoprazole led to a significantly high risk of COVID-19 positivity, pneumonia, and other upper and lower respiratory infections (**Supplementary Table S3**).

Intriguingly, the risk for developing pneumonia was higher among the *CYP2C19* rapid and ultrarapid metabolizers (aHR 1.45, 95% CI 1.22-1.73, $P < 0.001$) compared to normal, intermediate, or poor metabolizers (P for interaction < 0.001 , **Table 3**). Our analysis also demonstrated an increased risk of COVID-19 positivity among regular PPI users who are *CYP2C19* rapid and ultrarapid metabolizers (aHR 1.13, 95% CI 1.03-1.36, $P = 0.016$), while the risks for the other metabolizer groups were not significant (**Table 3**). For the risk of severe COVID-19, *CYP2C19* normal metabolizers demonstrated a significantly increased risk (aHR 1.44, 95% CI 1.06-1.95, $P = 0.019$; **Supplementary Table S4**), while the population for comparison was smaller.

3.5 Propensity score-matching analysis

Matching of 9,910 regular PPI users and 39,760 non-regular users (1:4 by propensity scores) was conducted, and the baseline characteristics were much more similar (**Supplementary Table S5**). The participants regularly exposed to PPIs were observed with increased risks for pneumonia (multivariable-adjusted HR 1.33, 95% CI 1.18-1.50, $P < 0.001$), influenza (multivariable-adjusted HR 1.33, 95% CI 1.12-1.58, $P < 0.001$), other upper respiratory infections (multivariable-adjusted HR 1.18, 95% CI 1.10-1.26, $P < 0.001$), and other lower respiratory infections (multivariable-adjusted HR 1.33, 95% CI 1.26-1.42, $P < 0.001$) (**Supplementary Table 6**), which were consistent with the results from Cox hazard proportional regression models. Nonsignificant associations were held for the endpoints of COVID-19 (**Supplementary Table 6-7**).

4. Discussion

In this large-scale, population-based cohort with updated information, we identify that regular use of PPIs is associated with incident pneumonia, influenza, as well as other upper and lower respiratory infections. In contrast, analyses of COVID-19-related outcomes, including positivity, severity, and mortality, do not reveal any increased risk after adjustments for confounding. In the subgroup analysis, regular PPI users with *CYP2C19* rapid metabolic phenotypes, or those without main indications, might suffer from a higher risk of developing respiratory infections.

For the past two decades, accumulating evidence indicates increased risks of pneumonia under the use of PPIs [7, 8, 20], whereas others failed to show such associations [9, 10]. Conflicting findings also exist for studies referring to the risk of COVID-19 outcomes among PPI users [11-14]. The correlation between PPI use and the risk of influenza remains unexplored. Compared with existing studies, our study more comprehensively adjusts for a variety of critical covariates with utilizing the latest data from the UK Biobank, and compares the risks among different types of *CYP2C19* metabolizers for the first time.

Our study reveals that the regular use of PPIs increases the risks of both pneumonia and influenza. Several proposed mechanisms can account for the association between the use of PPIs and respiratory infections. Since a gastric pH < 2 effectively inhibits colonization of ingested microbes, one critical issue is that reduced acidity induced by PPIs leads to the overgrowth of bacteria, which can contribute to the development of infections in the respiratory tract through microaspiration [21, 22]. It is observed that compared to untreated patients, PPI users have an increase of 6 to 12 times in the growth of *Staphylococcus*, *Streptococcus*, and *Veillonella* within the gastric fluid [23]. Under acid suppression, influenza virus genes are also detected in gastric mucosa, indicating the persistent existence of virus can also be contributed by PPI-induced low acidity [24]. Therefore, colonization and growth of pathogens including bacteria and viruses under hypochlorhydria could increase the risk of respiratory infections. In addition, the H⁺/K⁺-ATPase proton pumps are present in mucosal cells and ducts in the human lung, and the use of PPIs might disturb the composition of respiratory flora [25]. Alterations in the respiratory tract microbiome could contribute to the

development of pneumonia [26].

Angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2, is extensively expressed in the digestive tract, which indicates gastrointestinal infection of the virus [27]. In addition, a gastric pH of ≤ 2.5 effectively inactivates SARS-CoV-2 [28]. However, we did not identify an increased risk for COVID-19 positivity under the regular use of PPIs. The possible explanation is that the relatively smaller sample size, or the lack of re-evaluation for medication use prior to the COVID-19 pandemic might conceal the effects of PPIs [29].

Moreover, emerging evidence has revealed the inappropriate prescription of PPIs in both the primary and secondary care settings, and 33-67% of the patients did not take the drug according to their countries' criteria [30]. Similarly, the baseline characteristics of the included participants in our study demonstrate that approximately 60% of the regular PPI users do not have main indications. Administration of PPIs can rapidly increase intragastric pH to higher than 6 after 2-4 hours [31]. In consequence, their misuse might predispose individuals with normal gastric acid production to infection by pathogens compared to patients with excessive secretion, accounting for the observed higher risk of pneumonia and influenza among regular PPI users without main indications in our study. Unawareness of the impact of *CYP2C19* enzymes on metabolism also leads to PPI overutilization when the therapeutic effect is unsatisfied, regardless of re-evaluation for appropriate doses and strategy. Therefore, the observed increased risk for pneumonia in PPI recipients with rapid or ultrarapid *CYP2C19* metabolism compared to other types of metabolizers seems anomalous but reasonable. Taken together, misuse and overdoing could predispose PPI recipients to a greater risk of developing pneumonia and influenza.

Concerns over protopathic bias due to non-specific and overlapping symptoms between pneumonia/influenza and acid-related diseases were raised [32]. Nevertheless, pneumonia and influenza often present with acute cough, and other concomitant symptoms distinct from acid-related diseases [33]. In contrast, patients with chronic cough are more commonly GERD-related [33]. The American College of Chest Physicians Clinical Practice Guidelines for Management of Reflux-Cough Syndrome also recommend against using PPI therapy alone for patients with chronic cough but without heartburn or regurgitation [34]. In our study,

the use of PPIs is defined as taking the medication for most days of the week in the last 4 weeks, which is uncommon for acute cough. Although we cannot completely rule out protopathic bias, it is less likely to affect the outcomes.

Our study has several potential strengths. First, our study utilizes the updated large-sample data from the UK Biobank and exclusively includes participants with valid records from primary care, which reduces the information bias. Second, a variety of covariates, especially for the indications of PPIs and the use of aspirin, which might contribute to indication or protopathic bias, have been adjusted to enhance the robustness of our results. Third, genotypic data of metabolic enzymes has been integrated into our study. Furthermore, propensity score-matching analysis eliminates a greater portion of bias and derives consistent results.

Limitations inevitably exist in our study. Information on dose and duration of PPI use is currently not available from the UK Biobank, and therefore we cannot evaluate the effects of prolonged PPI use on the risk of respiratory infections. Additionally, PPIs are indicated for *Helicobacter pylori* (*H. pylori*) eradication, whereas the UK Biobank does not contain adequate data. Thus, the indication for eradicating *H. pylori* is not adjusted in this study. The data of COVID-19-related outcomes are relatively small in size, which limits the power. Moreover, due to the nature of observational study, the causality of PPI use on risks of respiratory infections cannot be established, and Mendelian randomization studies could be further conducted to explore the causal associations. Furthermore, the current study is principally based on white British ancestry in the United Kingdom, and future exploration of other ancestries with comparisons is warranted.

Our findings could have essential implications for the prevention of respiratory infections and the de-prescribing of PPIs in clinical practice. Misuse of PPIs without main indications might contribute to a greater risk of developing respiratory infections. Intriguingly, the risks of developing incident pneumonia and COVID-19 positivity are higher among *CYP2C19* rapid and ultrarapid metabolizers regularly taking PPIs compared to other types of metabolizers. Since our study exclusively involves participants with valid primary care data, such an increased risk might be contributed by the over-prescription or self-taking of PPIs under the

undesired effects without following the proper strategy. The significance of appropriate use of PPIs is therefore highlighted.

In conclusion, regular use of PPIs is associated with increased susceptibility to pneumonia and influenza, whereas no increased risk is observed for COVID-19 infection. It is noteworthy that PPI users without main indications might suffer from a higher risk of developing respiratory infections. Appropriate use and de-prescribing of PPIs are highlighted for patients and clinical practitioners. Further studies based on different doses and durations of PPIs are warranted.

Conflict of interest statement

The authors declared no conflict of interest.

Acknowledgement

The authors are grateful to the UK Biobank for approval and access to data of the project, and this research has been conducted under Application Number 83339.

Funding

This work is supported by the National Natural Science Foundation of China (82171698, 82170561, 81300279, 81741067), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).

References

- 1 Vaezi MF, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. **Gastroenterology** 2017;153:35-48.
- 2 Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in Prescription Drug Use Among Adults in the United States From 1999-2012. **Jama** 2015;314:1818-31.
- 3 Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on De-prescribing of proton pump inhibitors: expert review. **Gastroenterology** 2022.
- 4 Abtahi S, Driessen JHM, Burden AM, Souverein PC, van den Bergh JP, van Staa TP, *et al.* Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study. **Ann Rheum Dis** 2021;80:423-31.
- 5 Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. **Bmj** 2019;365:l1580.
- 6 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. **Nature Reviews Gastroenterology & Hepatology** 2017;14:697-710.
- 7 Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. **Jama** 2009;301:2120-8.
- 8 van der Sande L, Jöbsis Q, Bannier M, van de Garde EMW, Coremans JJM, de Vries F, *et al.* The risk of community-acquired pneumonia in children using gastric acid suppressants. **Eur Respir J** 2021;58.

- 9 Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. **Ann Intern Med** 2008;149:391-8.
- 10 Redelmeier DA, McAlister FA, Kandel CE, Lu H, Daneman N. Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. **Bmj** 2010;340:c2608.
- 11 Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors. **Am J Gastroenterol** 2020;115:1707-15.
- 12 Israelsen SB, Ernst MT, Lundh A, Lundbo LF, Sandholdt H, Hallas J, *et al.* Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis. **Clin Gastroenterol Hepatol** 2021;19:1845-54.e6.
- 13 Fan X, Liu Z, Miyata T, Dasarathy S, Rotroff DM, Wu X, *et al.* Effect of Acid Suppressants on the Risk of COVID-19: A Propensity Score-Matched Study Using UK Biobank. **Gastroenterology** 2021;160:455-8.e5.
- 14 Lee SW, Ha EK, Yeniova A, Moon SY, Kim SY, Koh HY, *et al.* Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. **Gut** 2021;70:76-84.
- 15 Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. **Bmj** 2016;355:i5813.
- 16 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. **PLoS medicine** 2015;12:e1001779.
- 17 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* The UK Biobank

resource with deep phenotyping and genomic data. **Nature** 2018;562:203-9.

18 Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, *et al.* Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. **Clin Pharmacol Ther** 2020.

19 Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, *et al.* Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. **J Clin Epidemiol** 2001;54:387-98.

20 Meijvis SC, Cornips MC, Voorn GP, Souverein PC, Endeman H, Biesma DH, *et al.* Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. **Eur Respir J** 2011;38:1165-72.

21 Lee AS, Ryu JH. Aspiration Pneumonia and Related Syndromes. **Mayo Clin Proc** 2018;93:752-62.

22 Savarino V, Di Mario F, Scarpignato C. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety. **Pharmacol Res** 2009;59:135-53.

23 Rosen R, Amirault J, Liu H, Mitchell P, Hu L, Khatwa U, *et al.* Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. **JAMA Pediatr** 2014;168:932-7.

24 Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. **J Gastroenterol** 2002;37:101-5.

25 Altman KW, Waltonen JD, Tarjan G, Radosevich JA, Haines GK, 3rd. Human lung mucous glands manifest evidence of the H⁺/K⁺-ATPase proton pump. **Ann Otol Rhinol Laryngol** 2007;116:229-34.

- 26 Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. **Lancet Respir Med** 2014;2:238-46.
- 27 Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, *et al.* SARS-CoV-2 productively infects human gut enterocytes. **Science** 2020;369:50-4.
- 28 Esseili MA. Great escape: how infectious SARS-CoV-2 avoids inactivation by gastric acidity and intestinal bile. **Gut** 2022.
- 29 Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, *et al.* Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern. **J Med Virol** 2022;94:2160-6.
- 30 Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. **Bmj** 2008;336:2-3.
- 31 Laine L, Shah A, Bermanian S. Intra-gastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. **Gastroenterology** 2008;134:1836-41.
- 32 Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case-control studies. **The American journal of medicine** 1980;68:255-8.
- 33 Irwin RS, French CL, Chang AB, Altman KW. Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report. **Chest** 2018;153:196-209.
- 34 Kahrilas PJ, Altman KW, Chang AB, Field SK, Harding SM, Lane AP, *et al.* Chronic Cough Due to Gastroesophageal Reflux in Adults: CHEST Guideline and Expert Panel Report. **Chest** 2016;150:1341-60.

Figure Legends

Figure 1. Flow diagram of eligible participants selection.

Figure 2. Stratified analysis of regular proton pump inhibitor (PPI) users and the risk of pneumonia, influenza, and COVID-19 infection. Effect estimates were based on age, sex, deprivation index, alcohol consumption, smoking, body mass index (BMI), indications of PPIs, hypertension, type 2 diabetes, chronic obstructive pulmonary disease (COPD), asthma, aspirin, histamine 2 receptor antagonist (H2RA), and cholesterol-lowering medication, using the fully adjusted model. CI: confidence interval; HR: hazard ratio; P_i: *P* value for interaction.

Table 1. Baseline characteristics of the included participants.

Characteristics	Regular PPI use		Overall
	Yes	No	
Number of participants, n (%)	9 997 (6.2)	150 926 (93.8)	160 923 (100.0)
Age, years, mean (SD)	59.4 (7.4)	56.3 (8.2)	56.5 (8.1)
Sex, female, n (%)	5 533 (55.4)	79 709 (52.8)	85 242 (53.0)
Ethnicity, white, n (%)	9 571 (95.7)	144 295 (95.6)	153 866 (95.6)
Deprivation index, mean (SD)	-0.9 (3.3)	-1.4 (3.0)	-1.4 (3.0)
Alcohol consumption, n (%)			
Daily or almost daily	1 805 (18.1)	28 846 (20.5)	32 874 (20.4)
3 or 4 times a week	1 923 (19.2)	33 533 (23.8)	37 570 (23.4)
1 or 2 times a week	2 396 (24.0)	37 443 (26.6)	42 228 (26.2)
1 to 3 times a month	1 179 (11.8)	15 669 (11.1)	17 988 (11.2)
Special occasions only	1 522 (15.2)	14 965 (10.6)	17 616 (11.0)
Never	1 161 (11.6)	10 414 (7.4)	12 570 (7.8)
Smoking, n (%)			
Never smoker	4 572 (45.7)	82 998 (55.0)	87 570 (54.4)
Previous smoker	4 289 (42.9)	52 013 (34.5)	56 302 (35.0)
Current smoker	1 136 (11.4)	15 915 (10.6)	17 051 (10.6)
Physical activity, MET minutes/week, median (IQR)	1 525.5 (2 722.0)	1 815.0 (2 848.5)	1 794.0 (2 838.5)
Fresh fruit intake, pieces, mean (SD)	2.0 (2.6)	1.9 (2.6)	1.9 (2.6)
BMI, kg/m², mean (SD)	29.2 (5.1)	27.4 (4.7)	27.5 (4.8)
Indication of PPIs, n (%)			
GERD	3 235 (32.4)	4 015 (2.7)	7 250 (4.5)
Peptic ulcer	561 (5.6)	1 303 (0.9)	1 864 (1.2)
Upper gastrointestinal bleeding	18 (0.2)	38 (0.03)	56 (0.03)
Comorbidities, n (%)			
Hypertension	4 116 (41.2)	38 162 (25.3)	42 278 (26.3)
Type 2 diabetes	124 (1.2)	890 (0.6)	1 014 (0.6)
Renal failure	60 (0.6)	243 (0.2)	303 (0.2)
Myocardial infarction	331 (3.3)	1 632 (1.1)	1 963 (1.2)
Stroke	140 (1.4)	943 (0.6)	1 083 (0.7)
COPD	46 (0.5)	200 (0.1)	246 (0.2)
Asthma	841 (8.4)	8 471 (5.6)	9 312 (5.8)
Medication use, n (%)			
Aspirin	2 457 (24.6)	21 108 (14.0)	23 565 (14.6)
Non-aspirin NSAIDS	1 224 (12.2)	22 568 (15.0)	23 792 (14.8)
H2RA	297 (3.0)	2 956 (2.0)	3 253 (2.02)
Cholesterol lowering medications	1 537 (15.4)	9 241 (6.1)	10 778 (6.70)
Multivitamin use, n (%)	2 227 (22.3)	33 201 (22.0)	35 428 (22.0)

BMI: body mass index; COPD: chronic obstructive pulmonary disease; GERD: gastroesophageal reflux disease; H2RA: histamine 2 receptor antagonist; IQR: interquartile range; MET: metabolic equivalent of task; PPI: proton pump inhibitor; NSAIDS: non-steroidal anti-inflammatory drugs; SD: standard deviation.

Table 2. Associations of PPI use with the susceptibility to pneumonia, influenza, COVID-19, and other respiratory infections.

	Case/person-years	Non-adjusted model		Age/sex-adjusted model		Fully adjusted model*	
		HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Pneumonia							
Non-regular PPI use	2 904/12 867	1.00 (reference)		1.00 (reference)		1.00 (reference)	
Regular PPI use	378/1 702	2.04 (1.83-2.27)	<0.001	1.74 (1.56-1.94)	<0.001	1.42 (1.26-1.59)	<0.001
Influenza							
Non-regular PPI use	2 009/6 011	1.00 (reference)		1.00 (reference)		1.00 (reference)	
Regular PPI use	183/539	1.38 (1.19-1.62)	<0.001	1.49 (1.28-1.74)	<0.001	1.31 (1.11-1.55)	0.001
COVID-19							
Non-regular PPI use	6 443/77 867	1.00 (reference)		1.00 (reference)		1.00 (reference)	
Regular PPI use	534/6 437	1.34 (1.23-1.47)	<0.001	1.26 (1.16-1.38)	<0.001	1.05 (0.95-1.16)	0.335
Other upper respiratory infections							
Non-regular PPI use	14 449/52 499	1.00 (reference)		1.00 (reference)		1.00 (reference)	
Regular PPI use	1 118/3 988	1.30 (1.22-1.38)	<0.001	1.31 (1.23-1.39)	<0.001	1.19 (1.11-1.27)	<0.001
Other lower respiratory infections							
Non-regular PPI use	14 494/55 384	1.00 (reference)		1.00 (reference)		1.00 (reference)	
Regular PPI use	1 486/5 598	1.78 (1.67-1.88)	<0.001	1.65 (1.56-1.74)	<0.001	1.37 (1.29-1.46)	<0.001

*Adjusted for age, sex, ethnicity, deprivation index, smoking, alcohol consumption, physical activity, fresh fruit intake, body mass index, any indication of PPIs (gastroesophageal reflux disease [GERD], peptic ulcer, upper gastrointestinal bleeding), comorbidities (hypertension, type 2 diabetes, renal failure, myocardial infarction, stroke, chronic obstructive pulmonary disease [COPD], asthma), medications (aspirin, non-aspirin non-steroidal anti-inflammatory drugs [NSAIDs, ibuprofen], histamine 2 receptor antagonists (H2RAs), cholesterol lowering medications), and multivitamin use.

CI: confidence interval; COVID-19: coronavirus disease 2019; HR: hazard ratio; PPI: proton pump inhibitor.

Table 3. Associations of PPI use with the risk of pneumonia, influenza, COVID-19, and other respiratory infections by *CYP2C19* phenotypes

	Case/Person-years	HR (95% CI)*	P	Pi
Pneumonia				<0.001
Non-regular PPI user	2 904/12 867	1.00 (reference)		
PPI user, <i>CYP2C19</i> rapid and ultrarapid metabolizers	146/626	1.45 (1.22-1.73)	<0.001	
PPI user, <i>CYP2C19</i> normal metabolizers	186/869	1.32 (1.13-1.55)	<0.001	
PPI user, <i>CYP2C19</i> likely intermediate, intermediate and poor metabolizers	2/14	1.24 (0.98-1.56)	0.078	
Influenza				0.757
Non-regular PPI user	2 009/6 011	1.00 (reference)		
PPI user, <i>CYP2C19</i> rapid and ultrarapid metabolizers	68/193	1.26 (0.98-1.62)	0.074	
PPI user, <i>CYP2C19</i> normal metabolizers	94/285	1.32 (1.06-1.65)	0.013	
PPI user, <i>CYP2C19</i> likely intermediate, intermediate and poor metabolizers	5/17	1.64 (0.68-3.96)	0.271	
COVID-19				0.647
Non-regular PPI user	6 443/77 867	1.00 (reference)		
PPI user, <i>CYP2C19</i> rapid and ultrarapid metabolizers	227/2 722	1.17 (1.03-1.36)	0.016	
PPI user, <i>CYP2C19</i> normal metabolizers	255/3 076	0.95 (0.83-1.09)	0.486	
PPI user, <i>CYP2C19</i> likely intermediate, intermediate and poor metabolizers	13/162	0.84 (0.49-1.46)	0.545	
Other upper respiratory infection				0.681
Non-regular PPI user	14 449/52 499	1.00 (reference)		
PPI user, <i>CYP2C19</i> rapid and ultrarapid metabolizers	392/1 416	1.10 (0.99-1.22)	0.078	
PPI user, <i>CYP2C19</i> normal metabolizers	609/2 151	1.26 (1.15-1.37)	<0.001	
PPI user, <i>CYP2C19</i> likely intermediate, intermediate and poor metabolizers	14/54	0.70 (0.42-1.19)	0.190	
Other lower respiratory infection				0.923
Non-regular PPI user	14 494/55 384	1.00 (reference)		
PPI user, <i>CYP2C19</i> rapid and ultrarapid metabolizers	546/2 049	1.32 (1.21-1.45)	<0.001	
PPI user, <i>CYP2C19</i> normal metabolizers	763/2 868	1.36 (1.26-1.47)	<0.001	
PPI user, <i>CYP2C19</i> likely intermediate, intermediate and poor metabolizers	26/104	1.19 (0.81-1.75)	0.379	

CI: confidence interval; COVID-19: coronavirus disease 2019; HR: hazard ratio; Pi: *P* for interaction among different types of metabolizers; PPI: proton pump inhibitor.

*Fully adjusted model

Figure 1




Figure 2

